• 1
    Ko BK, Kawano K, Murray JL, et al. Clinical studies of vaccines targeting breast cancer. Clin Cancer Res. 2003; 9: 3222-3234.
  • 2
    Slingluff CLJr, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using 4 melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003; 21: 4016-4026.
  • 3
    Peoples GE, Gurney JM, Hueman MT, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high risk breast cancer patients. J Clin Oncol. 2005; 23: 7536-7545.
  • 4
    Holmes JP, Benavides LC, Gates JD, et al. Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol. 2008; 26: 3426-3433.
  • 5
    Diefenbach CS, Gnjatic S, Sabbatini P, et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res. 2008; 14: 2740-2748.
  • 6
    Ohno S, Kyo S, Myojo S, et al. Wilm's tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Res. 2009; 29: 4779-4784.
  • 7
    Salazar LG, Fikes J, Southwood S, et al. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res. 2003; 9: 5559-5565.
  • 8
    Slingluff CL, Petroni GR, Olson W, et al. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol. 2008; 26: 4973-4980.
  • 9
    Chianese-Bullock KA, Irvin WPJr, Petroni GR, et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother. 2008; 31: 420-430.
  • 10
    Slingluff CL Jr, Petroni GR, Olson WC, et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res. 2009; 15: 7036-7044.
  • 11
    Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. 1998; 188: 2357-2368.
  • 12
    Hueman MT, Stojadinovic A, Storrer CE, et al. Analysis of naive and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine. Cancer Immunol Immunother. 2007; 56: 135-146.
  • 13
    Knutson KL, Disis ML. Augmenting T helper cell immunity in cancer. Curr Drug Targets Immune Endocr Metabol Disord. 2005; 5: 365-371.
  • 14
    Woll MM, Hueman MT, Ryan GB, et al. Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer. Int J Oncol. 2004; 25: 1769-1780.
  • 15
    Anderson BW, Peoples GE, Murray JL, et al. Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals. Clin Cancer Res. 2000; 6: 4192-4200.
  • 16
    Peoples GE, Holmes JP, Hueman MT, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res. 2008; 14: 797-803.
  • 17
    Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000; 96: 3102-3108.
  • 18
    Sokal JE. Measurement of delayed skin-test responses. N Engl J Med. 1975; 293: 501-502.
  • 19
    Gray D, Matzinger P. T cell memory is short-lived in the absence of antigen. J Exp Med. 1991; 174: 969-974.
  • 20
    Bachmann MF, Kundig TM, Hengartner H, Zinkernagel RM. Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells: T cell memory without “memory T cells”? Proc Natl Acad Sci U S A. 1997; 94: 640-645.
  • 21
    Kundig TM, Bachmann MF, Oehen S, et al. On the role of antigen in maintaining cytotoxic T-cell memory. Proc Natl Acad Sci U S A. 1996; 93: 9716-9723.
  • 22
    Lau LL, Jamieson BD, Somasundaram T, Ahmed R. Cytotoxic T-cell memory without antigen. Nature. 1994; 369: 648-652.
  • 23
    Tanchot C, Lemonnier FA, Perarnau B, Breitas AA, Rocha B. Differential requirements for survival and proliferation of CD8 naive or memory T cells. Science. 1997; 276: 2057-2062.
  • 24
    Murali-Krishna K, Lau LL, Sambhara S, Lemonnier F, Altman J, Ahmed R. Persistence of memory CD8 T cells in MHC class I-deficient mice. Science. 1999; 286: 1377-1381.
  • 25
    Schneider J, Gilbert SC, Blanchard TJ, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med. 1998; 4: 397-402.
  • 26
    Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res. 2002; 8: 1014-1018.
  • 27
    Slingluff CLJr, Petroni GR, Chianese-Bullock KA, et al. Immunologic and clinical outcomes of a randomized phase II trial of 2 multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res. 2007; 13: 6386-6395.
  • 28
    Klade CS, Wedemeyer H, Berg T, et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology. 2008; 134: 1385-1395.
  • 29
    Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006; 211: 214-224.
  • 30
    Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005; 115: 1616-1626.
  • 31
    Holmes JP, Gates JD, Benavides LC, et al. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2008; 113: 1666-1675.
  • 32
    Opferman JT, Ober BT, Aston-Rickardt PG. Linear differentiation of cytotoxic effectors into memory T lymphocytes. Science. 1999; 283: 1745-1748.
  • 33
    Hou S, Hyland L, Ryan KW, Portner A, Doherty PC. Virus-specific CD8+ T-cell memory determined by clonal burst size. Nature. 1994; 369: 652-654.
  • 34
    Anichini A, Vbegetti C, Mortarini R. The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother. 2004; 53: 855-864.
  • 35
    Mortarini R, Piris A, Maurichi A, et al. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res. 2003; 63: 2535-2545.